MedTrace Logo

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2026-04-20

No results posted yet for this study

Summary

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.

Conditions

Interventions

DRUG

LY4050784

Oral

DRUG

Pembrolizumab

Administered IV.

DRUG

Cisplatin

Administered IV.

DRUG

Carboplatin

Administered IV.

DRUG

Pemetrexed

Administered IV.

DRUG

Paclitaxel

Administered IV.

DRUG

Nab paclitaxel

Administered IV.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-19
Primary Completion
2027-10-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Japan
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06561685 on ClinicalTrials.gov